Yearly donanemab doses for people with Alzheimer disease who finished an earlier donanemab study
Tests yearly donanemab doses in people who completed an earlier donanemab study.
Plain-language title generated from the registry record
Registry title: A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Key facts
- Where
- Austin, Aventura, Beaumont, Bellevue, Boise, Bolivar, Bradenton, Chicago, Clermont, Dayton, Daytona Beach, Gainesville, Greenacres City, Houston, Huntington Beach, Indianapolis, Irvine, Jacksonville, Lady Lake, Lake Charles, Las Vegas, Lima, Long Beach, Maitland, Merritt Island, Miami, Miami Lakes, Monroe, Mt. Dora, New Port Richey, Newton, Orlando, Pensacola, Phoenix, Port Orange, Riverside, Sacramento, San Diego, Santa Ana, Santa Rosa, Shavano Park, Southfield, Springfield, Tacoma, Tampa, The Villages, Walnut Creek, Waltham, Waterloo, Winter Park, and Woodstock, United StatesSee the 55 sites
- Phase
- Phase 3
Where in United States
- Senior Adults Specialty ResearchAustin, United StatesTaking people
- VIN - AventuraAventura, United StatesTaking people
- Gadolin ResearchBeaumont, United StatesTaking people
- Northwest Clinical Research CenterBellevue, United StatesTaking people
- Northwest Clinical TrialsBoise, United StatesTaking people
- Citizens Memorial Hospital DistrictBolivar, United StatesTaking people
- Bradenton Research Center, Inc.Bradenton, United StatesTaking people
- Great Lakes Clinical Trials - AndersonvilleChicago, United StatesTaking people
- K2 Medical Research WINTER GARDENClermont, United StatesTaking people
- NDx Clinical Research Inc.Dayton, United StatesTaking people
- K2 Medical Research - Daytona BeachDaytona Beach, United StatesTaking people
- Center for Advanced Research & EducationGainesville, United StatesTaking people
- Finlay Medical ResearchGreenacres City, United StatesTaking people
- The University of Texas Health Science Center at HoustonHouston, United StatesTaking people
- Care Access - Huntington BeachHuntington Beach, United StatesTaking people
- Care Access - South IndianapolisIndianapolis, United StatesTaking people
- Josephson Wallack Munshower Neurology, PCIndianapolis, United StatesTaking people
- Irvine Clinical ResearchIrvine, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- K2 MEDICAL Research THE VILLAGESLady Lake, United StatesTaking people
- Care Access - Lake Charles (Bayou Pines)Lake Charles, United StatesTaking people
- Vector Clinical TrialsLas Vegas, United StatesTaking people
- Care Access - LimaLima, United StatesTaking people
- Healthy Brain ClinicLong Beach, United StatesTaking people
- K2 Medical Research ORLANDOMaitland, United StatesTaking people
- Merritt Island Medical Research, LLCMerritt Island, United StatesTaking people
- Finlay Medical ResearchMiami, United StatesTaking people
- VIN-Andrew LermanMiami, United StatesTaking people
- Indago Research & Health Center, IncMiami Lakes, United StatesTaking people
- Monroe Biomedical ResearchMonroe, United StatesTaking people
- Adult Medicine of Lake County, Inc.Mt. Dora, United StatesTaking people
- Suncoast Clinical Research, Inc.New Port Richey, United StatesTaking people
- Boston Center for MemoryNewton, United StatesTaking people
- Charter Research - OrlandoOrlando, United StatesTaking people
- Headlands Research OrlandoOrlando, United StatesTaking people
- Emerald Coast Neurology - Airport BoulevardPensacola, United StatesTaking people
- Banner Alzheimer's InstitutePhoenix, United StatesTaking people
- Progressive Medical ResearchPort Orange, United StatesTaking people
- Artemis Institute for Clinical ResearchRiverside, United StatesTaking people
- Headlands Research- SacramentoSacramento, United StatesTaking people
- Artemis Institute for Clinical ResearchSan Diego, United StatesTaking people
- Syrentis Clinical ResearchSanta Ana, United StatesTaking people
- Providence Medical FoundationSanta Rosa, United StatesTaking people
- Consano Clinical Research, LLCShavano Park, United StatesTaking people
- Revival Research Institute, LLCSouthfield, United StatesTaking people
- The Cognitive and Research Center of New JerseySpringfield, United StatesTaking people
- Universal Research GroupTacoma, United StatesTaking people
- Care Access - TampaTampa, United StatesTaking people
- K2 Medical Research - TampaTampa, United StatesTaking people
- Charter Research The VillagesThe Villages, United StatesTaking people
- Infectious Disease Doctors Medical Group, APCWalnut Creek, United StatesTaking people
- MedVadis Research CorporationWaltham, United StatesTaking people
- Covenant Medical CenterWaterloo, United StatesTaking people
- Conquest ResearchWinter Park, United StatesTaking people
- North Georgia Clinical ResearchWoodstock, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07602582
- Record updated
- 28 October 2026
- Original description
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.Read full original descriptionShow less
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
Inclusion: Have completed study AACM Addendum 7; Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities; Are individuals assigned female at birth who are not of childbearing potential, or are individuals assigned male at birth; Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion: Current serious or unstable illnesses that, in the investigator's opinion, could interfere with participation in this study; Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker; Have had history of amyloid-targeting therapy treatment outside donanemab trials; Have any intracranial abnormality or lesion, including but not limited to macrohemorrhage, inflammation, or structural findings that, in the opinion of the investigator, may pose an unacceptable safety risk to the participant. Screening MRI finding of amyloid-related imaging abnormalities with edema (ARIA-E) may be monitored for resolution; Contraindication to florbetapir F 18 PET; Have participated, within the last 30 days, in a clinical trial involving a study intervention judged not to be scientifically or medically compatible with this study.